Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

A personalized mRNA vaccine appeared to reduce the chances of pancreatic cancer returning after surgery, according to a study ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published ...

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

In a small trial, 8 of 16 patients responded well to the mRNA vaccine The vaccine is personalized, based on each patient’s ...

an experimental approach to treating the cancer with a messenger RNA (mRNA)-based therapeutic vaccine "continues to show potential" in reducing the risk of the disease returning after surgery ...